What Shukra Pharmaceuticals does

Shukra Pharmaceuticals is an Indian pharmaceutical manufacturer founded in 1993 (one source notes 1992) and headquartered in Ahmedabad, Gujarat. The company operates WHO-GMP certified manufacturing facilities and distributes pharmaceutical formulations across more than 25 countries, supported by over 10 regional offices across India. Shukra is publicly listed on both BSE (524632) and NSE (SHUKRAPHARM), with a reported market capitalization of approximately USD 203 million, and currently employs between 101-250 people. Its core revenue derives from branded and generic pharmaceutical formulations sold through distribution networks serving hospitals, pharmacies, and government health programs.

For FY2025-26 the company reported revenue of Rs 56.73 crore (approximately USD 6.75 million) and a net profit of Rs 22.06 crore, implying a five-year CAGR of 244%. Beyond its traditional pharmaceutical business, Shukra is executing a deliberate pivot into medical technology, exemplified by its partnership with Borns Medical Robotics for surgical robotics and the development of AI-enabled products such as Cervicare AI. The MedTech move signals an effort to migrate up the value chain from commodity generics toward differentiated, technology-enabled medical devices and digital health offerings.

Shukra's growth strategy combines organic pharmaceutical expansion with substantial capital deployment, including a Rs 600 crore manufacturing facility planned in Greater Noida that is expected to create over 900 direct jobs. The combination of public market access, geographic reach across 25+ countries, a regulatory-certified manufacturing base, and MedTech diversification positions the company at an inflection point between traditional pharma manufacturing and next-generation medical technology. The substantial gap between current headcount (101-250) and planned headcount (900+) underscores the magnitude of the operational build-out underway.

Name

Shukra Pharmaceuticals

Legal name

Shukra Pharmaceuticals Limited

Website

https://shukrapharmaceuticals.com

Company type

Public

Founded year

1993

Operating status

Operating

Headcount range

101–250 employees

Short description

Shukra Pharmaceuticals is an Ahmedabad-based WHO-GMP certified pharmaceutical manufacturer serving 25+ countries, publicly listed on BSE and NSE, transitioning into MedTech through surgical robotics partnerships and AI-enabled products like Cervicare AI.

Ownership category

akta.pro rank

Product category

Pharmaceutical and Medical Technology Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industry

Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD)

Keywords

• Generic pharmaceuticals manufacturing
• Medical technology devices
• Surgical robotics systems
• Cardiac medical devices
• Diagnostic imaging equipment

Headquarters

HQ city

Ahmedabad

HQ country

India

HQ region

Asia

Offices10 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Products: Generic tablets, capsules, and injectables manufacturing and distribution for Indian and global markets including Africa, Southeast Asia, and CIS regions
2. Medical Technology Devices: Sale of advanced medical devices including surgical robotics, cardiac devices, diabetes technologies, diagnostic solutions, imaging equipment, and wound care products
3. Surgical Robotics Systems: AI-enabled surgical robotic systems targeting the India and APAC markets through joint venture B&S Robotics Private Limited

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Shukra Pharmaceuticals manufactures and distributes generic pharmaceutical formulations (tablets, capsules, injectables, ampoules, vials, prefilled syringes) and a diversified portfolio of medical technology devices spanning surgical robotics, cardiac devices, diabetes monitoring, diagnostic solutions, imaging equipment, wound care, and cancer therapy systems. The company serves hospitals and healthcare institutions in India and across Africa, CIS, Southeast Asia, and Latin America through direct sales and international distribution partners.

Product overview

Shukra Pharmaceuticals is a diversified healthcare company transitioning from traditional pharmaceuticals into a broad medical technology ecosystem. The company operates across ten product verticals through two main divisions: Shukra Pharmaceuticals (pharmaceutical formulations including tablets, capsules, injectables, ampoules, vials, and prefilled syringes for India, Africa, CIS, and Southeast Asia) and Shukra MedTech (advanced medical technologies spanning Surgical Robotics with the Veer Surgical Robot; Diabetes Technologies including Diaveer, InsuVeer, and Insu Smart; Cardiac Sciences with stents, TAVR, OCT, and heart valves; Diagnostic Solutions including proton and ion beam therapy; Imaging & Critical Care with AI-powered Cervicare AI, cath labs, and ICU equipment; Medical Simulations with virtual dissection tables and SkillLab solutions; Wound Care with silicone foam dressings; BNCT cancer therapy; and Virtual Autopsy & Forensic Sciences through the SEVA division). The portfolio addresses India's significant medical technology gap where 70-80% of advanced MedTech devices are imported, with products ranging from consumer-facing monitoring devices to sophisticated surgical robotics and cancer therapy systems.

Differentiator

Problem solved

Functional benefit

Brands

• Shukra MedTech: Medical technology division expanding across nine high-growth verticals including surgical robotics, diabetes technologies, cardiac sciences, diagnostic solutions, imaging and critical care, medical simulations, wound care, and BNCT
• SEVA
• Shukra Robotics
• Shukra AI Private Limited
• Veer Surgical Robot
• DIAVEER
• INSU VEER
• INSU SMART
• VizTouch
• Cervicare AI
• RakshaVeer
• ParamRakshaVeer
• Clinics on Cloud
• SkillLab

Products and services

• Surgical Robotics Next-generation minimally invasive robotic surgical systems for precision surgery, including soft tissue, ortho, neuro, and dental surgical robotics, featuring the Veer Surgical Robot.
• Diabetes Technologies Integrated continuous glucose monitoring and insulin delivery management systems for diabetes care, including Diaveer CGM, InsuVeer, Insu Smart, Multi Function Meter, and Dia Kit.
• Cardiac Sciences
• Advanced Surgical Solutions
• Diagnostic Solutions
• Imaging and Critical Care
• Medical Simulations
• Wound Care
• BNCT (Boron Neutron Capture Therapy) A novel targeted radiation therapy for cancer combining nuclear science, targeted therapy, and precision medicine, to be manufactured at the upcoming Greater Noida facility.
• Virtual Autopsy and Forensic Sciences (SEVA)
• Generic Pharmaceutical Products WHO-GMP certified generic pharmaceutical formulations including tablets, capsules, injectables, ampoules, vials, and prefilled syringes distributed across India, Africa, CIS, Southeast Asia, and Latin America.

Quantifiable outcome

• Revenue increased 74.07% year-over-year to Rs 56.73 crore in FY2025-26
• +4 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature10 records

Partnerships

Four partnerships are on record, tiered flagship and core.

• Borns Medical RoboticsflagshipStrategic or Co-development Partner · 14 August 2026Joint venture B&S Robotics Private Limited (60:40 ownership) focused on AI-enabled surgical robotic systems targeting India and APAC markets. Shukra contributes capital and distribution networks while Borns provides technology and manufacturing expertise. Definitive agreements expected within 120 days with long-term goal of potential stock exchange listing.
• Borns Medical Robotics Inc.coreTechnology or Integration · 18 March 2026Strategic partnership for developing surgical robotics and BNCT cancer therapy systems as part of Shukra's plan to invest Rs 600 crore in manufacturing facility in Greater Noida under Make in India initiative.
• YEIDA (Yamuna Expressway Industrial Development Authority)coreOthers · 6 February 2026Received Letter of Intent from YEIDA for land parcel to establish Rs 600 crore manufacturing facility in Greater Noida for advanced surgical robotics and Boron Neutron Capture Therapy technology. Project to create over 900 direct jobs.
• Born Medical Robotics Inc.coreStrategic or Co-development Partner · 7 January 2026Non-binding MoU to introduce and commercialize AI-powered surgical robotic systems in India and select South Asian markets including Nepal, Bangladesh, Sri Lanka, Maldives, and Bhutan. Partnership executed through Shukra Robotics subsidiary leveraging Shukra's regulatory execution capabilities and distribution reach alongside Borns' surgical medical robotics expertise.

Scale indicators17 records

Recent moves10 records

Expansion highlights6 records

Broad incumbents

• Aurobindo Pharma: Major Indian generic pharmaceutical manufacturer with extensive emerging market distribution. Comparable in pharmaceutical product mix and African/CIS market exposure.
• Stryker: Global medical technology leader with surgical robotics (Mako), cardiac, and orthopedic portfolios. Represents the global incumbent that Shukra's MedTech division must compete with in advanced device categories.
• Lupin: Indian pharmaceutical company with strong generic formulations portfolio and global presence. Comparable business model in pharmaceutical manufacturing with focus on emerging markets.
• Cipla: Large Indian pharmaceutical manufacturer with global distribution across Africa, Asia, and emerging markets. Shares the pharmaceutical formulations business model and emerging market distribution strategy, though at vastly larger scale.
• Intuitive Surgical: Global leader in surgical robotics (da Vinci systems). Sets the technology benchmark that Shukra's Veer Surgical Robot must compete against in India and APAC markets.

Direct peers

• PolyMedicure: Indian medical devices company manufacturing surgical consumables, cardiac devices, and similar medical technology products. Direct overlap in cardiac, surgical, and wound care product categories targeting hospital customers.
• SS Innovations International: Indian medical technology company developing the SSI Mantra surgical robotic system. Both companies target the India surgical robotics market with cost-effective alternatives to imported systems, competing for similar hospital customers in the same white-space opportunity.

Emerging players

• Transasia Bio-Medicals: Indian in-vitro diagnostics and medical equipment company. Comparable in targeting diagnostic solutions and medical equipment for Indian hospitals with focus on affordable alternatives to imported devices.
• Trivitron Healthcare: Indian medical technology company with focus on medical imaging, diagnostics, and surgical solutions. Comparable in building India-based MedTech portfolio across multiple verticals and targeting import substitution.

Regional players

• Wipro GE Healthcare: India-focused medical technology joint venture combining GE Healthcare technology with Wipro's India reach. Comparable business model of bringing advanced MedTech to Indian market and addressing import dependency.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Shukra Pharmaceuticals